Clinical Scorecard: Evaluation of Growth Hormone Treatment Following Pediatric Hematopoietic Cell Transplantation: A Nationwide Survey and Longitudinal Analysis
At a Glance
Category
Detail
Condition
Growth impairment in childhood hematopoietic cell transplantation survivors
Key Mechanisms
Radiation-related hypothalamic–pituitary injury, chronic graft-versus-host disease, and endocrine disruption
Target Population
Children who underwent hematopoietic cell transplantation and have post-transplant short stature
Care Setting
Multicenter pediatric oncology and transplant clinics
Key Highlights
GH therapy significantly improves final height SDS in treated patients compared to untreated patients.
Factors such as total body irradiation and chronic graft-versus-host disease are linked to poorer height outcomes.
GH therapy does not increase the risk of slipped capital femoral epiphysis, secondary malignancies, or disease relapse.
Guideline-Based Recommendations
Diagnosis
Confirm GH deficiency biochemically in childhood cancer and HCT survivors.
Management
Initiate GH therapy for patients with confirmed GH deficiency and short stature post-HCT.
Monitoring & Follow-up
Assess height outcomes using final adult height SDS and changes in SDS over time.
Risks
Monitor for potential complications associated with GH therapy, although risks appear low.
Patient & Prescribing Data
Survivors of childhood hematopoietic cell transplantation with short stature
Responses to GH therapy are heterogeneous; factors influencing responsiveness include transplant type and patient sex.
Clinical Best Practices
Optimize GH therapy based on individual patient factors and transplant-related complications.
Develop strategies for patients expected to respond poorly to GH therapy.
